Ceptaris Therapeutics is a privately held specialty pharmaceutical company based in Malvern, Pa., developing a proprietary gel formulation of mechlorethamine hydrochloride for treatment of early-stage (stages I–IIA) mycosis fungoides (CTCL). If approved, the investigational drug would be the first topical mechlorethamine product available to treat signs and symptoms of this rare cancer. The company recently received a Complete Response Letter from the FDA on its New Drug Application for the mechlorethamine gel and is working with the agency to address the requests. Ceptaris raised $10 million in a Series D-1 private placement of preferred stock to provide additional capital for ongoing activities. The financing included prior investors Vivo Ventures, Palo Alto Investors, Burrill & Company, Aperture Venture Partners, Osage, and BioAdvance, plus new investor Third Point, LLC. The company said the funds will be used for operational expenses, including activities related to addressing the FDA’s requests. Ceptaris Therapeutics is a privately held specialty pharmaceutical company in Malvern, Pa., developing a proprietary gel formulation of mechlorethamine hydrochloride for early-stage (stages I‑IIA) mycosis fungoides, a type of Cutaneous T‑Cell Lymphoma. The company's New Drug Application (NDA) for the mechlorethamine gel is under review by the U.S. Food and Drug Administration. If approved, the product would be the first topical mechlorethamine available to treat the signs and symptoms of this rare cancer. Ceptaris secured $15 million in venture debt financing to support ongoing operations and preparation for commercialization. It received $7.5 million at closing and has access to the remaining $7.5 million contingent on FDA approval of the NDA. Primary venture capital investors include Vivo Ventures, Palo Alto Investors, Burrill & Company, Osage Ventures, Aperture Venture Partners, and BioAdvance. Yaupon Therapeutics is a privately held specialty pharmaceutical company developing a proprietary gel formulation of mechlorethamine hydrochloride to treat early-stage (I‑IIA) mycosis fungoides, the most common type of cutaneous T‑cell lymphoma (CTCL). The company has submitted a New Drug Application (NDA) to the FDA for its investigational topical mechlorethamine gel. If approved, the product would be the first topical mechlorethamine gel widely available to treat signs and symptoms of this form of CTCL. Yaupon says the financing will fund the company through the NDA regulatory review and support preparation for commercialization. Management has stated commercialization may be pursued alone or with an industry partner. The company is based in Malvern, Pennsylvania.

Total raised

$39M

Funding rounds

3

Latest round

Series D

Latest activity

Jun 2012